27th week of 2010 patent applcation highlights part 39 |
Patent application number | Title | Published |
20100173828 | A (X - 38 .. 43) oligomers, and processes, compositions, and uses thereof - The present invention relates to an Aβ(X-38 . . . 43) oligomer having a high molecular weight, or a derivative thereof, a process for preparing the oligomer or derivative, compositions comprising the oligomer or derivative, and uses of the oligomer or derivative such as its use for treating or preventing an amyloidosis (e.g. by active immunization), for diagnosing an amyloidosis, and for providing agents that are capable of binding to the Aβ(X-38 . . . 43) oligomer or derivative. The subject invention also describes agents that are capable of binding to the Aβ(X-38 . . . 43) oligomer or derivative, e.g. antibodies, compositions comprising the agents, and uses of the agents such as their use for treating or preventing an amyloidosis (e.g. by passive immunization) and for diagnosing an amyloidosis. | 2010-07-08 |
20100173829 | Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof - The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α | 2010-07-08 |
20100173830 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 2010-07-08 |
20100173831 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 2010-07-08 |
20100173832 | ANTICANCEROUS POLYMERIC AGENTS - Methods and pharmaceutical compositions for treating cancer, particularly MDR cancer, which utilize polymeric compounds that are composed of a plurality of amino acid residues and one or more hydrophobic moieties are disclosed. | 2010-07-08 |
20100173833 | METHODS AND COMPOSITION FOR USE OF CYCLIC ANALOGUES OF HISTATIN - Provided are novel compositions and therapeutic methods for treating bacterial and fungal disease with cyclic analogues of histatin. The cyclic analogues of histatin are advantageously more potent but less toxic than currently used anti-microbial agents. In addition, compositions comprising the cyclic analogue with other anti-microbial agents such as azole compounds are disclosed. | 2010-07-08 |
20100173834 | CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS - The present invention is directed to compounds according to formula, (R | 2010-07-08 |
20100173835 | Peptides for Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 2010-07-08 |
20100173836 | NOVEL MACROCYCLES - Disclosed herein are compounds of general formula (I): | 2010-07-08 |
20100173837 | DOSING FORMS AND REGIMENS COMPRISING 3-[(R)-2-(N,N-DIMETHYLAMINO)ETHYLTHIO-SAR]-4-(GAMMAHYDROXYMETHYLLEUCINE)C- YCLOSPORINE - Provided herein are specific doses of, and dosing regimens for, using SCY-635 in treating or preventing diseases, in particular hepatitis C virus (HCV) infection. | 2010-07-08 |
20100173838 | NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES - The invention concerns a novel method for preparing an intermediate polyanion for preparing cyclosporin derivatives by treating a cyclosporin with a hexamethyldisilazane metal salt, optionally in the presence of a metal halide. The treated cyclosporin has one or several free hydroxy groups and/or non-methylated nitrogen atoms in position α and/or any other acid group capable of deprotonation which are optionally deprotonated or in protected form. | 2010-07-08 |
20100173839 | STABILIZED INSULIN-LIKE GROWTH FACTOR POLYPEPTIDES - The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented. | 2010-07-08 |
20100173840 | Pharmaceutical Composition for Treating Autoimmune, Allergic and Inflammatory Diseases and Delivery Method Thereof - Disclosed herein are a novel pharmaceutical composition for inhibiting autoimmune diseases, allergic diseases and inflammatory diseases, which contains a conjugate of Foxp3 and PTD (protein transduction domain), and a delivery method thereof. According to the disclosed invention, Foxp3-PTD treats and inhibits autoimmune diseases by effectively inhibiting the activation of T cells in a mouse autoimmune disease model. | 2010-07-08 |
20100173841 | Highly Purified Type A Botulinum Toxin Preparation From Infant Botulism Pathogen - A novel type A | 2010-07-08 |
20100173842 | VACCINE FOR STAPHYLOCOCCAL INFECTIONS - The invention relates to a method of preparation and use of a polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology. | 2010-07-08 |
20100173843 | TISSUE ADHERING COMPOSITIONS - A method mixes a first component, a second component, and a buffer material. The first component includes an electrophilic polymer material comprising poly(ethylene glycol) having a functionality of at least three. The second component includes a nucleophilic material comprising a natural or synthetic protein at a concentration of about 25% or less that, when mixed with the first component within a reaction pH range, cross-links with the first component to form a non-liquid, three-dimensional barrier. The buffer material includes tris-hydroxymethylaminomethane having a pH within the reaction pH range. The method applies the mixture to adhere to a tissue region. | 2010-07-08 |
20100173844 | Stable Formulations of Peptides - Stable pharmaceutical composition comprising insulinotropic peptide. | 2010-07-08 |
20100173845 | USE OF FERTIRELIN AND DELTA-ENDORPHIN AS THERAPEUTIC AGENTS - The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-NHEt as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-NHEt optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-07-08 |
20100173846 | MAGNESIUM AMMONIUM PHOSPHATE CEMENT COMPOSITION - This invention relates to a cement, which comprises in its main phase of microcrystalline magnesium ammonium phosphate and nanoapatite after hardening and thus at the same time has considerable strength. The material is biologically degradable and is suitable for application in tooth cements, as bone replacement, as bone filler, as bone cement or as bone adhesive. | 2010-07-08 |
20100173847 | TFPI INHIBITORS AND METHODS OF USE - The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject. | 2010-07-08 |
20100173848 | Methods of inhibiting chemokine binding to chemokines receptors - Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides. | 2010-07-08 |
20100173849 | NEO-TRYPTOPHAN - Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75, NT76, or NT77. | 2010-07-08 |
20100173850 | Improved Peptide Composition - A peptide sequence of the form: X(Lys,Arg)XXXXX(Arg,Lys)X, wherein Lys and Arg arc replaceable and X is preferably one or more of the following amino acids: hydrophobic amino acid residues (eg Pro, Leu. Met, Ile), basic amino acid residues or threonine; and wherein the sequence is capable of engaging Λβ and ameliorating its SOD activity and/or metal ion binding. | 2010-07-08 |
20100173851 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds. | 2010-07-08 |
20100173852 | USE OF AGENTS THAT DOWN-REGULATE EXPRESSION OF TANIS AND/OR P21 Waf1/Cip1/Sd1 GENES, AND USE OF AGENTS THAT INHIBIT, DEGRADE, SEQUESTER OR PREVENT THE NEUROTOXICITY OF GENE PRODUCT PROTEINS OF TANIS AND P21 Waf1/Cip1/Sd1 GENES - The present invention provides compositions and methods for treating glaucoma, ocular hypertension, and age-related macular degeneration. More specifically, the present invention describes the use of agents that down-regulate expression of tanis and/or p21 | 2010-07-08 |
20100173853 | COMBINATION OF MONOSACCHARIDES WITH ASCORBIC ACID AND USE THEREOF - Composition containing a combination of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, and of at least one additional compound chosen from ascorbic acid, an analogue thereof and a mixture thereof. The present invention also relates to the use of such a composition for combating the signs of ageing, and also to a device containing the composition. | 2010-07-08 |
20100173854 | Microfluidized Oil-in-water Emulsions and Vaccine Compositions - This invention provides submicron oil-in-water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions containing an antigen combined with such emulsions intrinsically or extrinsically. Methods of preparing the emulsions and vaccines are also provided by the present invention. | 2010-07-08 |
20100173855 | Dermatological Formulations - Aqueous preparations of substantially equimolor amounts of a zinc salt and clindamycin phosphate form a polymer useful in the topical treatment of acne and rosacea, with very low systemic levels of clindamycin. | 2010-07-08 |
20100173856 | METHODS OF PRODUCING AND USING NUTRITIONAL AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ONE OR MORE ACTIVE SUBSTANCES - Methods for producing a composition that includes an active agent, nutraceutical and pharmaceuticals compositions, and methods for ameliorating and/or treating a disease using the composition that includes an active substance are described herein. More particularly, methods for producing a composition that contains one or more active substances such as oleocanthal, pharmaceutical compositions that include one or more active substances such as oleocanthal, and methods of ameliorating and/or treating inflammation using compositions that contains one or more active substances such as oleocanthal are described. | 2010-07-08 |
20100173857 | Spinosyns For Wound Healing - A spinosyn or a physiologically acceptable derivative or salt thereof for promoting or accelerating wound healing in humans. | 2010-07-08 |
20100173858 | COMPOSITIONS TO TREAT BACTERIAL AND INFLAMMATORY AFFECTIONS IN PET ANIMALS DOSAGE FORM AND METHOD TO TREAT PET ANIMALS - Compositions comprising at least one bactericidal antibiotic from the group of macrolides and a non-steroid anti-inflammatory with selective inhibiting activity for cycloxygenase 2 (COX-2). The present invention also refers to a dosage form of said compositions, as well as a method to treat pet animals, particularly dogs and cats. Compositions of the present invention are particularly useful for administration to provide animals with dosages of about 1.0 to 50 mg of compound A/kg of body weight of the animal and about 0.05 to 5.0 mg of compound B/kg of body weight of the animal, being compound A preferably azithromycin and compound B, meloxicam. | 2010-07-08 |
20100173859 | PHARMACEUTICAL FORMULATION FOR THE PRODUCTION OF RAPIDLY DISINTERGRATING TABLETS - Pharmaceutical formulation in the form of compacts comprising
| 2010-07-08 |
20100173860 | Purifications of Pomegranate Ellagitannins and Their Uses Thereof - Compositions of purified and biologically active ellagitannins are provided by separation from pomegranate husk using a method of extraction and purification using a solid polymeric adsorbent and the uses of the said compounds | 2010-07-08 |
20100173861 | COMBINATIONAL PARADIGM COMBATING HIV, HIV/HSV, OR HIV/HPV INFECTIONS IN HUMANS USING SMALL MOLECULAR WEIGHT COMPOUNDS FROM PLANTS - Compounds, compositions and methods for the treatment of HIV/HSP/HPV, in particular, compositions and methods for a 3 part combination therapy for HIV/HSV/HPV, comprising a viral attachment inhibitor, a viral sequence integration inhibitor, and a proviral transcription inhibitor. The therapy is advantageous for the treatment of HIV infection, and is also effective for HSV and HPV infection. Also disclosed are novel viral attachment inhibitors and methods of use. | 2010-07-08 |
20100173862 | INJECTABLE, INJECTION SOLUTION, AND INJECTION KIT PREPARATION - Provided is an injectable comprising: an anthracycline antineoplastic antibiotic; and at least one acid amide selected from the group consisting of nicotinic acid amide, isonicotinic acid amide and gentisic acid ethanolamide. | 2010-07-08 |
20100173863 | 2-Fluoronucleosides - 2′-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: | 2010-07-08 |
20100173864 | COMPOSITIONS INCLUDING TRICIRIBINE AND ONE OR MORE PLATINUM COMPOUNDS AND METHODS OF USE THEREOF - This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2010-07-08 |
20100173865 | Anti-Cancer Agent-Hyaluronic Acid Conjugate Compositions and Methods - Methods of making conjugates comprising an anti-cancer agent and hyaluronic acid, together with mixtures of reaction products comprising such conjugates and methods of using such conjugates in therapeutic and research applications are disclosed. | 2010-07-08 |
20100173866 | APPARATUS AND METHOD FOR OCULAR TREATMENT - The invention provides tools, materials and related methods to surgically access the suprachoroidal space of an eye for the purpose of performing minimally invasive surgery or to deliver drugs to the eye. The invention provides a flexible microcannula or microcatheter device ( | 2010-07-08 |
20100173867 | INJECTABLE CROSS-LINKED POLYMERIC PREPARATIONS AND USES THEREOF - A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue. | 2010-07-08 |
20100173868 | Composition and method for healing tissues - The composition and method for healing tissues is a medicinal composition for facilitating the growth, protection and healing of tissues and cells in animals and humans. The composition is formulated as a either a powder, gel, paste, film, fluid injectable, rehydratable freeze-dried paste or sponge, sprayable solution, topically applied patch with adhesive and reservoir system, an intermediate for coatables such as films and bandages, a matrix for membranes, or as a matrix of flexible polymer(s), or delivered as either an orally ingestible liquid, tablet or capsule. The main ingredient of the formulated compositions is hydrolyzed collagen, which can be combined with polysulfated glycosaminoglycans, hyaluronic acid or salts thereof, or a glucosamine salt, and mixtures thereof. The composition may be formulated as an aqueous eye drop solution. | 2010-07-08 |
20100173869 | TREATMENT OF SURFACTANTS - The invention relates to a method for treatment of a surfactant, in particular a pulmonary surfactant. The method is further established in that the surfactant is treated with a lipid sequestrating or cholesterol sequestrating surfactant treatment agent, in which given, in particular neutral lipids or cholesterol are selectively sequestrated by means of the surfactant treatment agent, such that the effect of the lipids and/or the effect of the cholesterol on the surfactant is reduced or reversed. | 2010-07-08 |
20100173870 | Phosphonate Compounds - The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like. | 2010-07-08 |
20100173871 | PHOSPHORYLATED DENDRIMERS AS ANTIINFLAMMATORY DRUGS - A method for treating inflammatory diseases through an anti-inflammatory type activation of monocytes, the method includes the administration to a patient in need thereof of an effective quantity of at least one dendrimer with mono- or biphosphonic terminations. | 2010-07-08 |
20100173872 | Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin - A composition and method of treating Alzheimer's disease or a dementia of vascular origin are disclosed. The composition and method utilize an endothelin antagonist as the active agent to treat Alzheimer's disease or a dementia of vascular origin in mammals, including humans. | 2010-07-08 |
20100173873 | TREATMENT OF METASTASIZED TUMORS - Methods of treating metastatic cancer such as metastasized tumors include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The compound, tautomer, salt of the compound, salt of the tautomer, or mixture thereof may be used to prepare medicaments for treating metastatic cancer. The variable A has the values defined herein. | 2010-07-08 |
20100173874 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear - The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus. | 2010-07-08 |
20100173875 | Formulation of aspirin that is stable and showing minimal hydrolysis for parenteral adminstration for the treatment of cardiovascular and other disease states - Disclosed herein are ways to solubilize aspirin for parenteral administration containing aspirin and a diluent NNDMA (N,N-Dimethylacetamide) useful in the treatment of acute coronary syndromes as well as other disease states. The solution so constituted is stable at room temperature for prolonged periods without decomposition and avoids significant hydrolysis of the aspirin and thus the loss of the anti-platelet action when stored. | 2010-07-08 |
20100173876 | OIL-BASED NSAID COMPOSITIONS AND METHODS FOR MAKING AND USING SAME - A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration. | 2010-07-08 |
20100173877 | MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN - The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase prepration is characterized by a first phase consisting of 2 daily dose dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenon and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenon, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo. | 2010-07-08 |
20100173878 | ORGANIC COMPOUNDS - 2-benzyl-3-(optionally hetero)arylamino-[2H]-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-diones, in free, salt or prodrug form, are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors. | 2010-07-08 |
20100173880 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF - Alkaloid aminoester compounds which act as muscarinic receptor antagonists are useful for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases. | 2010-07-08 |
20100173881 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The invention features methods and compositions for the treatment of immunonflammatory disorders. | 2010-07-08 |
20100173882 | Steroidal Compositions - Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein. | 2010-07-08 |
20100173883 | 7-HYDROXYEPIANDROSTERONE HAVING NEUROPROTECTIVE ACTIVITY - 3-Hydroxy-7β-hydroxy steroids and 3-oxo-7β-hydroxy steroids and pharmaceutically acceptable esters thereof are useful for protection against neuronal damage. | 2010-07-08 |
20100173884 | USE OF A PHYTOSTEROL CONTAINING COMPOSITION FOR THE TREATMENT OF LUTS - The invention relates to the use of a composition comprising an oil-extract and a water-soluble extract, wherein said extracts are obtainable from plant materials and said extracts comprise phytosterols, for the manufacturing of a medicament for the treatment of females suffering from LUTS as a consequence of Interstitial Cystitis and/or stress or urge incontinence. | 2010-07-08 |
20100173885 | ORGANOMETEALLIC COMPOUNDS - The present invention relates to novel organometallic compounds for use as a medicine, in particular in photodynamic therapy against various diseases, such as cancer or inflammatory and/or immune disorders. The compounds comprise a central porphyrin or phtalocyanine backbone to which ligand linkers coordinated to at least one transition metal are attached. Eta-5 or eta-6 arenes further bind to the transition metal. According to a preferred embodiment, the compound is a tetranuclear Ruthenium (+II) complex. | 2010-07-08 |
20100173886 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity. | 2010-07-08 |
20100173887 | BACTERICIDAL ANTI-MRSA ACTIVE PHARMACEUTICAL COMPOSITION CONTAINING CARBAPENEMS - Pharmaceutical compositions containing a carbapenem of the structural formula I | 2010-07-08 |
20100173888 | Nicotinamide Derivatives - The present invention relates to compounds of the formula (I) | 2010-07-08 |
20100173889 | Substituted Pyrimidine and Triazine Compounds - Substituted pyrimidine and triazine compounds corresponding to formula I | 2010-07-08 |
20100173890 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease - The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in the treatment of 5-HT6 mediated disorders such as Alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and Parkinson's disease. | 2010-07-08 |
20100173891 | HETEROCYCLIC COMPOUNDS, METHODS FOR THE PREPARATION THEREOF, AND USES THEREOF - The compounds of the present invention are of formula I: | 2010-07-08 |
20100173892 | Enantioselective synthesis of 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,1-JK][1]-benzazepin-2[1H- ]-one and zilpaterol - This invention relates to a process for the hydrogenation of a ketooxime to selectively form an aminoalcohol stereoisomer, and, in particular, to a process for the hydrogenation of 4,5-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,6,7[1H]-trione-6-oxime or a salt thereof to selectively form a stereoisomer of 6-amino-7-hydroxy-4,5,6, 7-tetrahydro-imidazo[4,5,1-jk][1]-benzazepin-2[1H]-one or a salt thereof. This invention also relates to the use of the 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,1-jk][1]-benzazepin-2[1H]-one hydrogenation product or a salt thereof to selectively make a stereoisomer of zilpaterol or a salt thereof, as well as the use of such a zilpaterol stereoisomer or salt in methods of treatment and medicaments for animals. | 2010-07-08 |
20100173893 | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation - A process for preparing a compound of the formula IA or IB: | 2010-07-08 |
20100173894 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES - The present invention relates to certain 1-substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives of Formula (I), that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2C receptor associated diseases, conditions or disorders, such as, obesity and related disorders. | 2010-07-08 |
20100173895 | IMIDAZOLOPYRIMIDINES AND IMIDAZOLOTRIAZINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) - The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo-or radiosensitizers for cancer treatment. | 2010-07-08 |
20100173896 | Organic Compounds - The present invention relates to novel benzodiazepine compounds exhibiting RXR-antagonist efficacy, to the manufacture and to the use thereof. | 2010-07-08 |
20100173897 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). | 2010-07-08 |
20100173898 | SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides of formula (I). | 2010-07-08 |
20100173899 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS - Disclosed are novel dipeptide analogs compounds of Formula (I), (II) or (III): | 2010-07-08 |
20100173900 | Strobilurins for Increasing the Resistance of Plants to Abiotic Stress - The present invention relates to a method for increasing the resistance of a plant or of a plant's seed to abiotic stress which method comprises treating the seed from which the plant is to grow with at least one | 2010-07-08 |
20100173901 | Substituted Heterocyclic Compounds - The present invention relates to substituted heterocyclic compounds of Formula I: | 2010-07-08 |
20100173902 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses - This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as conditions such as stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment. | 2010-07-08 |
20100173903 | Bicyclic amide derivatives for the treatmet of respiratory disorders - This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin. In a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment. | 2010-07-08 |
20100173904 | Topical composition, topical composition precursor, and methods for manufacturing and using - A tropical composition is provided. The topical composition can be prepared by diluting a topical composition precursor with water and adding additional components, if desired. The topical composition precursor can be prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups wherein the alkylene groups contain at least 10 carbon atoms, and a hydrophilic polymer composition including repeating carboxylic groups and/or repeating hydroxyl groups. A topical composition precursor and methods for manufacturing and using a topical composition are provided by the invention. | 2010-07-08 |
20100173905 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME - The invention discloses a new use of a class of heptacyclic compounds in the preparation of formulations for the prevention and treatment of diabetes and metabolic syndromes; the present invention also discloses a new class of heptacyclic compounds; the present invention also discloses a process for preparing the heptacyclic compounds and a composition containing the same. The heptacyclic compounds of the present invention can be used to effectively preventing or treating diseases such as diabetes and metabolic syndromes. | 2010-07-08 |
20100173906 | Substituted 3,4,6,7-Tetrahydro-5H-1,2a,4a,8-Tetraazacyclopenta[cd]Phenalenes and Methods - Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalene-9-amines, pharmaceutical compositions containing the compounds or salts thereof, intermediates, methods of making the compounds or salts thereof, and methods of use of these compounds or salts thereof or pharmaceutical compositions as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed. | 2010-07-08 |
20100173907 | Method of treatment of aggression - The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity. | 2010-07-08 |
20100173908 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine ureas of formula (I). | 2010-07-08 |
20100173909 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 - Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described. | 2010-07-08 |
20100173910 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS - The present invention relates to triaminopyrimidine derivatives of formula (I) | 2010-07-08 |
20100173911 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES - Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists. | 2010-07-08 |
20100173912 | Novel Compound - The invention provides 5-fluoro-2-[4-({[(4-fluorophenyl)methyl]oxy}acetyl)-1-piperazinyl]benzonitrile of formula (I), | 2010-07-08 |
20100173913 | PYRIDO-AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROLIFERATIVE AGENTS - The present invention concerns the compounds of formula | 2010-07-08 |
20100173914 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Compounds that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning. | 2010-07-08 |
20100173915 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE COMPOUND - Disclosed herein is a therapeutic agent for chronic heart failure comprising, as an effective ingredient, 5-[2-propyloxy-5-(1-methyl-2-pyrrolidinyl-ethylamidosulfonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one. The compound inhibits phosphodiesterase-5 (PDE-5), which catalyzes the intracellular degradation of cyclic guanosine monophosphatase (cGMP), thereby mitigating several signs of chronic heart failure, that is, thereby preventing left ventricular dilatation, decreasing ventricular wall thinning, lowering elevated cardiac and circulating levels of atrial natriuretic peptide (ANP), and inhibiting ventricular fibrosis. Also, the compound has advantages in that it reaches the maximal plasma level in a short time, has an in vivo half-life longer than conventional PDE-5 inhibitors, allowing decreased administration frequency, and has fewer side effects, thus ensuring safety. Thus, the compound is useful as a therapeutic agent for chronic heart failure. | 2010-07-08 |
20100173916 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions - The present invention relates to substituted xanthines of general formula | 2010-07-08 |
20100173917 | UREA DERIVATIVES AS ABL MODULATORS - The invention provides methods and compositions for treating conditions mediated by Bcr-Abl. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects. | 2010-07-08 |
20100173918 | METHODS AND COMPOSITIONS FOR DETERMINING THE EFFICACY OF BREAST CANCER THERAPEUTICS - The present disclosure relates to a method, kit and controls for detecting phosphorylated Tyr | 2010-07-08 |
20100173919 | PHARMACEUTICAL COMPOSITION USING ALISKIREN AND AVOSENTAN - The present invention relates to a pharmaceutical composition and method of achieving a therapeutic effect including, but not limited to, the treatment of hypertension, kidney or heart disease in an animal, preferably a mammal including a human subject, using (i) SPP100/aliskiren or a pharmaceutically acceptable salt thereof in combination with (ii) SPP301/avosentan or a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier. | 2010-07-08 |
20100173920 | POLYMORPHS OF 3-(E)-2--3-METHOXYACRYLATE - The present invention relates to novel crystalline polymorphic and amorphous forms of the compound (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxy-acrylate(azoxystrobin). Infrared Raman spectra, X-ray powder diffraction pattern and differential scanning calorimetry thermogram of two polymorphs “A” and “B” are provided. Further, the present invention also provides methods for preparing the novel polymorphic forms “A” and “B”, as well as processes for producing mixtures of the polymorphs, and a process for preparing amorphous azoxystrobin. Yet further, the present invention provides anti-fungal compositions comprising the novel crystalline polymorphs “A” and “B” or amorphous azoxystrobin, which are useful for controlling and combating fungi grown on agricultural and horticultural crops and up-land, and methods of using the same as pesticidal agents for combating fungi on agricultural and horticultural crops. | 2010-07-08 |
20100173921 | Antiretroviral Solid Oral Composition - The present invention provides an antiretroviral solid oral composition comprising one or more antiretroviral drugs, for example protease inhibitors such as lopinavir, ritonavir or a combination thereof with one or more excipients. The invention provides a composition which is smaller for a given amount of said active substance and possesses taste masking property and a process for preparing the composition. The present invention also provides an antiretroviral solid oral composition comprising one or more antiretroviral drugs, for example protease inhibitors such as lopinavir, ritonavir or a combination thereof with at least one water insoluble polymer, wherein the ratio of drug to polymer in the composition ranges from about 1:1 to about 1:6, and a process for preparing the composition. | 2010-07-08 |
20100173922 | Polymorphisms for Predicting Disease and Treatment Outcome - The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response. | 2010-07-08 |
20100173923 | 4 (PYRROLOPYRIDINYL)PYRIMIDINYL-2-AMINE DERIVATIVES - Compounds of the formula I in which R | 2010-07-08 |
20100173924 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF - The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (I): which penetrate the blood-brain barrier, inhibit the formation and accumulation of beta-amyloid, and are useful in the treatment of neurodegenerative diseases, particularly Alzheimer's disease. Further, the compounds of the present invention inhibit certain kinases, thereby being useful for the treatment of cancers of the central nervous system. | 2010-07-08 |
20100173925 | OXYINDOLE DERIVATIVES - This invention relates to compounds of the formula (I): | 2010-07-08 |
20100173926 | Methods for Regulating Neurotransmitter Systems by Inducing Counteradaptations - The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to period between administrations of no greater than ½. The methods of the present invention may be used to address a whole host of undesirable mental, neurological and physiological conditions. | 2010-07-08 |
20100173927 | BELOXEPIN AND ANALOGS FOR THE TREATMENT OF PAIN - This present disclosure provides methods of treating pain with beloxepin and/or beloxepin analogs. | 2010-07-08 |
20100173928 | Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex - In certain aspects, the invention relates to methods for identifying compounds which modulate Akt activity mediated by the rictor-mTOR complex and methods for treating or preventing a disorder that is associated with aberrant Akt activity. | 2010-07-08 |